1. 297 FLOW CYTOMETRIC ANALYSIS OF MATURATION-ASSOCIATED STAGES OF CD34+ POPULATIONS IN THE BONE MARROW OF MDS PATIENTS. Issue 1 (April 2015) Authors: Gardikas, N.; Vikentiou, M.; Konsta, E.; Kapsimali, V.; Kontos, C.; Ioannidou, E.; Economopoulou, C.; Bouhla, A.; Roumpakis, C.; Papanikolaou, N.; Vasilatou, D.; Papageorgiou, S.; Dimitriadis, G.; Pappa, V. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Allogeneic hematopoietic stem cell transplantation for the treatment of patients with refractory mycosis fungoides/Sezary syndrome: a single center experience. (2019) Authors: Papadavid, E.; Pappa, V.; Nikolaou, V.; Hliakis, T.; Gkirkas, K.; Stamouli, M.; Karagiannidi, A.; Thomopoulos, T.; Theodoropoulos, K.; Tsirigotis, P. Journal: European journal of cancer Issue: Volume 119(2019)Supplement 1 Page Start: S34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Augmented apoptotic efficacy of brentuximab vedotin combined with lenalidomide in CD-30 expressing Sézary syndrome cell lines. (2019) Authors: Bakou, V.; Spathis, Aris; Bouhla, Anthi; Glezou, Eirini; Stavroulaki, Georgia; Thomopoulos, T.; Gkontopoulos, Konstantinos; Pappa, V.; Papadavid, E. Journal: European journal of cancer Issue: Volume 119(2019)Supplement 1 Page Start: S18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T‐Cell lymphomas patients. (28th February 2019) Authors: Papadavid, E.; Kapniari, E.; Marinos, L.; Nikolaou, V.; Oikonomidi, A.; Georgakopoulos, J.; Stratigos, A.; Kouloulias, V.; Pappa, V. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 5(2019) Page Start: e223 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Immune Cell Density as a Predictive Index for Response to Treatment and Outcome of High Risk MDS Treated with 5-Azacytidine. (April 2017) Authors: Tsakiraki, Z.; Papageorgiou, S.; Spathis, A.; Bouchla, A.; Bazani, E.; Glezou, E.; Karakitsos, P.; Panayiotides, I.; Pappa, V.; Foukas, P. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. In vitro effect of Jak and HDAC inhibitors in cutaneous T-cell lymphoma. (2019) Authors: Karagianni, F.; Saraki, K.; Papadaki, M.; Mpakou, V.; Piperi, C.; Pappa, V.; Papadavid, E. Journal: European journal of cancer Issue: Volume 119(2019)Supplement 1 Page Start: S4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Lenalidomide Induces Responses in Patients with MDS-DEL(5)Q Alone, or with One Additional Abnormality, Irrespective of Who Classification and Prognostic Categorization. (April 2017) Authors: Symeonidis, A.; Kouraklis-Symeonidis, A.; Galanopoulos, A.; Hatzimichael, E.; Zikos, P.; Vassilakopoulos, T.; Pappa, V.; Kotsianidis, I.; Dimou, M.; Palla, K.; Viniou, N.A.; Kartasis, Z.; Pontikoglou, C.; Barbarousi, D.; Pagoni, M.; Xanthopoulidis, G.; Kotsopoulou, M.; Michali, E.; Katodritou, E.... Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity. (17th August 2021) Authors: Papadavid, E.; Kapniari, E.; Pappa, V.; Nikolaou, V.; Iliakis, T.; Dalamaga, M.; Jonak, C.; Porkert, S.; Engelina, S.; Quaglino, P.; Ortiz‐Romero, P.L.; Vico, C.; Cozzio, A.; Dimitriou, F.; Guiron, R.; Guenova, E.; Hodak, E.; Bagot, M.; Scarisbrick, J. Journal: British journal of dermatology Issue: Volume 185:Number 5(2021) Page Start: 1035 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity. (1st November 2021) Authors: Papadavid, E.; Kapniari, E.; Pappa, V.; Nikolaou, V.; Iliakis, T.; Dalamaga, M.; Jonak, C.; Porkert, S.; Engelina, S.; Quaglino, P.; Ortiz‐Romero, P.L.; Vico, C.; Cozzio, A.; Dimitriou, F.; Guiron, R.; Guenova, E.; Hodak, E.; Bagot, M.; Scarisbrick, J. Journal: British journal of dermatology Issue: Volume 185:Number 5(2021) Page Start: 1035 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P1629: ADMINISTRATION OF CONVALESCENT PLASMA FOR THE TREATMENT OF SEVERE COVID-19: RESULTS OF A MULTICENTER PHASE II TRIAL. (23rd June 2022) Authors: Thomopoulos, T.; Bouchla, A.; Antoniadou, A.; Terpos, E.; Politou, M.; Stamoulis, K.; Koromboki, E.; Papageorgiou, S.; Kotanidou, A.; Kalomenidis, I.; Jahaj, E.; Grigoropoulou, S.; Pagoni, M.; Grouzi, E.; Poulakou, G.; Trontzas, I.; Labropoulou, S.; Mentis, A.; Bamias, A.; Tsiodras, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗